{"id":815615,"date":"2025-02-20T08:48:20","date_gmt":"2025-02-20T13:48:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-announces-positive-data-from-phase-2a-trial-of-sls009-in-combination-with-zanubrutinib-in-dlbcl\/"},"modified":"2025-02-20T08:48:20","modified_gmt":"2025-02-20T13:48:20","slug":"sellas-announces-positive-data-from-phase-2a-trial-of-sls009-in-combination-with-zanubrutinib-in-dlbcl","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-announces-positive-data-from-phase-2a-trial-of-sls009-in-combination-with-zanubrutinib-in-dlbcl\/","title":{"rendered":"SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL"},"content":{"rendered":"
\n

\n – Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; <\/em>
\n 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients<\/em>
\n –<\/em>\n <\/p>\n

\n – Median Overall Survival Not Reached Yet \u2013 67% of Patients Still Alive –<\/em>\n <\/p>\n

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (\u201cSELLAS\u2019\u2019 or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced data from Phase 2a trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed\/refractory Diffuse Large B-Cell Lymphoma (r\/r DLBCL).<\/p>\n

The trial, conducted and funded by GenFleet Therapeutics (Shanghai), Inc. (\u201cGenfleet\u201d), was an open-label single-arm multicenter Phase 2a study in China evaluating SLS009 in combination with BTK inhibitor, Brukinsa\u00ae (zanubrutinib) in r\/r DLBCL. The results showed an overall response rate of 67%, more than double the expected overall response rate (ORR) of zanubrutinib alone. Among responders, one achieved complete response (CR), while three had partial response (PR) with target lesion shrinkages of 89%, 78%, and 56%, respectively. As of the last follow-up, after the median of 4.6 (range: 1.4 – 7.4) months follow-up, median overall survival (OS) was not reached, and six out of 9 patients were alive.<\/p>\n

\u201cThese results represent a promising step forward in improving outcomes for DLBCL patients and underscores the potential of SLS009 in combination with zanubrutinib to deliver meaningful clinical benefits,\u201d said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. \u201cAchieving an ORR that significantly exceeds expectations, along with a complete response and multiple partial responses is a testament to the power of collaboration and innovation in tackling this challenging disease. We believe that the combination of SLS009 and zanubrutinib demonstrates a synergy that could pave the way for more effective treatment options. Moving forward, GenFleet will determine the next steps regarding the trial\u2019s continuation around lymphoma as SELLAS\u2019 focus remains in AML and spliceosome \u2013 chromatin mutations, including ASXL1 mutations.\u201d<\/p>\n

\n Summary of Phase 2a data of SLS009 in DLBCL<\/strong>\n <\/p>\n

\n Patients Characteristics<\/strong>\n <\/p>\n